Title : What is new in heart failure?
Heart failure is a common clinical syndrome that is characterized by frequent hospitalization and increased mortality. The mortality rate after one year is between 20 to 30% and increases to about 50% after 5 years, despite improvements in pharmacotherapy and device therapy.
Consequently, the worlds attention has shifted to research in the field of heart failure with numerous ongoing clinical trials undertaken in heart failure to try and reduce this global burden. The definition of heart failure was changed by the European Society of Cardiology and now focuses on new ejection fraction definitions with clear diagnostic criteria.
Several new drugs have been included in Heart Failure Guidelines such as the Sacuitril/Valsartan compound which is the first in a class of Angiotensin Receptor Neprilysin Inhibitor (ARNI). In addition, iron therapy, the role of Soluble Guanylate Cyclase (sGC) compounds and Sodium-glucose Cotransporter-2 (SGLT2) inhibitors in heart failure will be discussed.